Essentials of Atrial Fibrillation

  • Yee Guan Yap
  • A John Camm

Table of contents

  1. Front Matter
    Pages I-VIII
  2. Yee Guan Yap, John Camm
    Pages 1-5
  3. Yee Guan Yap, John Camm
    Pages 7-10

About this book


This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. ​Atrial fibrillation (AF) affects an estimated 1–2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events.


Atrial Fibrillation Cardiology Direct factor Xa inhibitors Oral Anticoagulants Rivaroxaban

Authors and affiliations

  • Yee Guan Yap
    • 1
  • A John Camm
    • 2
  1. 1.Consultant Interventional Cardiologist,Prince Court Medical Centre, Kuala Lumpur, MalaysiaHead and Associate Professor of Cardiology,Putra University, Selangor, MalaysiaKuala LumpurMalaysia
  2. 2.Honorary Consultant Cardiologist,St George’s Hospital, London, UKProfessor of Clinical Cardiology,Division of Clinical Sciences,St George’s University of London, London, UKLondonUnited Kingdom

Bibliographic information

  • DOI
  • Copyright Information Springer Healthcare 2014
  • Publisher Name Springer Healthcare, Tarporley
  • eBook Packages Medicine
  • Print ISBN 978-1-85873-438-5
  • Online ISBN 978-1-907673-98-6
  • Buy this book on publisher's site